S-adenosylmethionine, a methyl donor, up regulates tissue inhibitor of metalloproteinase-2 in colorectal cancer

Genetics and Molecular Research

Volumn 12, Issue 2, 2013, Pages 1106-1118

  Hussain, Z ^a   Khan, M I ^b   Shahid, M ^c   Almajhdi, F N ^d  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Colorectal cancer; DNA hypomethylation; Epigenetics; Gene expression; Metastasis

Indexed keywords

GELATINASE A; PROTEIN P21; S ADENOSYLMETHIONINE; SMAD2 PROTEIN; SMAD4 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; UROKINASE; VASCULOTROPIN;

ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETIC REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; P21 GENE; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SMAD2 GENE; SMAD4 GENE; TGF BETA GENE; TIMP 2 GENE; UPREGULATION;

EID: 84876256052     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.April.10.6     Document Type: Article

References (40)

1. Ateeq B, Unterberger A, Szyf M and Rabbani SA (2008). Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10: 266-278.
2. Baylin SB, Esteller M, Rountree MR, Bachman KE, et al. (2001). Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10: 687-692.
3. Bird NC, Mangnall D and Majeed AW (2006). Biology of colorectal liver metastases: A review. J. Surg. Oncol. 94: 68-80.
4. Brown R and Strathdee G (2002). Epigenomics and epigenetic therapy of cancer. Trends Mol. Med. 8: S43-S48.
5. Carmeliet P and Jain RK (2000). Angiogenesis in cancer and other diseases. Nature 407: 249-257.
6. Chiang PK, Gordon RK, Tal J, Zeng GC, et al. (1996). S-Adenosylmethionine and methylation. FASEB J. 10: 471-480.
7. DeClerck YA, Perez N, Shimada H, Boone TC, et al. (1992). Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52: 701-708.
8. Detich N, Hamm S, Just G, Knox JD, et al. (2003). The methyl donor S-Adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-Adenosylmethionine. J. Biol. Chem. 278: 20812-20820.
9. Ehrlich M (2002). DNA methylation in cancer: too much, but also too little. Oncogene 21: 5400-5413.
10. Esteller M (2005). DNA methylation and cancer therapy: new developments and expectations. Curr. Opin. Oncol. 17: 55-60.
11. Esteller M, Corn PG, Baylin SB and Herman JG (2001). A gene hypermethylation profile of human cancer. Cancer Res. 61: 3225-3229.
12. Futschik M, Jeffs A, Pattison S, Kasabov N, et al. (2002). Gene expression profiling of metastatic and nonmetastatic colorectal cancer cell lines. Genome Lett. 1: 26-34.
13. Galm O, Suzuki H, Akiyama Y, Esteller M, et al. (2005). Inactivation of the tissue inhibitor of metalloproteinases-2 gene by promoter hypermethylation in lymphoid malignancies. Oncogene 24: 4799-4805.
14. Gokaslan ZL, Chintala SK, York JE, Boyapati V, et al. (1998). Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors. Clin. Exp. Metastasis 16: 721-728.
15. Gomez DE, Alonso DF, Yoshiji H and Thorgeirsson UP (1997). Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74: 111-122.
16. Hajitou A, Sounni NE, Devy L, Grignet-Debrus C, et al. (2001). Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res. 61: 3450-3457.
17. Imren S, Kohn DB, Shimada H, Blavier L, et al. (1996). Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 56: 2891-2895.
18. Ivanova T, Vinokurova S, Petrenko A, Eshilev E, et al. (2004). Frequent hypermethylation of 5' flanking region of TIMP-2 gene in cervical cancer. Int. J. Cancer 108: 882-886.
19. Jemal A, Siegel R, Ward E, Hao Y, et al. (2008). Cancer statistics, 2008. CA Cancer J. Clin. 58: 71-96.
20. Kerbel RS (2008). Tumor angiogenesis. N. Engl. J. Med. 358: 2039-2049.
21. Kretzschmar M (2000). Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer. Breast Cancer Res. 2: 107-115.
22. Liotta LA, Tryggvason K, Garbisa S, Hart I, et al. (1980). Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68.
23. Liotta LA, Steeg PS and Stetler-Stevenson WG (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336.
24. Mazar AP, Henkin J and Goldfarb RH (1999). The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 3: 15-32.
25. McMillan DC and McArdle CS (2007). Epidemiology of colorectal liver metastases. Surg. Oncol. 16: 3-5.
26. Mollabashy A and Scarborough M (2000). The mechanism of metastasis. Orthop. Clin. North Am. 31: 529-535.
27. Pakneshan P, Szyf M, Farias-Eisner R and Rabbani SA (2004). Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J. Biol. Chem. 279: 31735-31744.
28. Parkin DM, Bray F, Ferlay J and Pisani P (2001). Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94: 153-156.
29. Pulukuri SM, Patibandla S, Patel J, Estes N, et al. (2007). Epigenetic inactivation of the tissue inhibitor of metalloproteinase-2 (TIMP-2) gene in human prostate tumors. Oncogene 26: 5229-5237.
30. Rao JS (2003). Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 3: 489-501.
31. Razin A and Riggs AD (1980). DNA methylation and gene function. Science 210: 604-610.
32. Rothbarth J and van de Velde CJ (2005). Treatment of liver metastases of colorectal cancer. Ann. Oncol. 16: 144-149.
33. Shukeir N, Pakneshan P, Chen G, Szyf M, et al. (2006). Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 66: 9202-9210.
34. Stetler-Stevenson WG, Aznavoorian S and Liotta LA (1993). Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol. 9: 541-573.
35. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, et al. (2002). A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31: 141-149.
36. Valente P, Fassina G, Melchiori A, Masiello L, et al. (1998). TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer 75: 246-253.
37. Yamamoto M, Mohanam S, Sawaya R, Fuller GN, et al. (1996). Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res. 56: 384-392.
38. Yi JM, Dhir M, Guzzetta AA, Iacobuzio-Donahue CA, et al. (2012). DNA methylation biomarker candidates for early detection of colon cancer. Tumour. Biol. 33: 363-372.
39. Yin JJ, Selander K, Chirgwin JM, Dallas M, et al. (1999). TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103: 197-206.
40. Yoon SO, Kim MM and Chung AS (2001). Inhibitory effect of selenite on invasion of HT1080 tumor cells. J. Biol. Chem. 276: 20085-20092.